WASHINGTON, DC — SEPTEMBER 21, 2010 — A new drug-eluting stent design demonstrated superiority over a traditional drug-eluting stent at 6 months, according to a study led by Laura Mauri, MD, Associate Professor of Medicine, Brigham and Women’s H…
In the Life After Cancer Epidemiology (LACE) study, 1,897 participants diagnosed with early-stage breast cancer between 1997 and 2000 and recruited on average 2 years post-breast cancer diagnosis were evaluated for the association between alcohol …
Clinical descriptors can assist clinicians in identifying patients with various stages of atherothrombosis (abnormal fatty deposits in an artery) who are at high-risk of future cardiovascular events, according to a study that will appear in the Sept…
Eating oily fish like salmon, tuna or bluefish at least twice a week can prevent sudden cardiac death because fatty acids in the fish block dangerous irregular heart rhythms, experts say in a review article in today’s of Circulation: Journal of the American Heart Association.
Most women who die from an abrupt loss of heart function (called sudden cardiac death) have no prior history of heart disease. However, 94 percent of these women have at least one cardiac risk factor such as smoking, high blood pressure, high cholesterol, diabetes or obesity, according to a report in today’s rapid access issue of Circulation: Journal of the American Heart Association.
Drug company AstraZeneca said it has submitted an application to the U.S. Food and Drug Administration for approval of quetiapine (Seroquel) as a treatment for acute mania associated with bipolar disorder, or manic-depressive illness. The application follows the completion of a clinical trial programme in bipolar disorder undertaken by the company which reportedly found quetiapine effective as a treatment of acute mania on two levels: as monotherapy (i.e to be prescribed on its own) and as adjunctive therapy with standard mood stabilising medication. These clinical trials have delivered strong and positive results in both the monotherapy and adjunctive therapy studies, which confirm quetiapine to be an ideal first line therapy for the treatment of acute mania associated with bipolar disorder, the company said.